MEDICINE BEYOND BORDERS

Providing Manufacturing Breakthroughs That Lower the Cost of Life Saving Drugs

MEDICINE BEYOND BORDERS

Providing Manufacturing Breakthroughs That Lower the Cost of Life Saving Drugs

Medicine Beyond Borders

Providing the World's Disease Epicenters with Millions of Prescriptions for NCD's and Infectious Diseases.

  • Malaria

  • Cancer

  • Orphan Drugs

  • Acute Respiratory Infections

  • GI Infections

  • COVID 19

  • Dengue Fever
  • AIDS and other STD's

  • Tuberculosis

About Zoar Limited

Zoar is an established pharmaceutical company dedicated to the development and manufacturing of specialized and complex active pharmaceutical ingredients (APIs) and orphan drugs. The company's expertise spans across various critical health areas, including malaria, cancer, gastrointestinal disorders, acute respiratory infections, COVID-19, dengue fever, tuberculosis, and other infectious diseases.

Under the visionary leadership of Dr. Kanans Visvanants FRSC (Dr. Kanans), a second-generation pharmaceutical and chemical engineer, the company revolutionized the industry by significantly reducing the cost of manufacturing generic and patented drugs. With proprietary and advanced technologies, the company provides over 300 million annual medical doses to the world's disease epicenters, addressing both non-communicable diseases (NCDs) and infectious diseases.

Oncology (Cancer)

Hormonal Therapies

Antibiotics (Bacterial Infections)

Cardiovascular Diseases

Neurological Disorders

Antiviral Treatments

0
Countries
0+
Million Annual Doses
0
Products
0+
Distributors
0
Countries
0+
Million Annual Doses
0
Products
0+
Distributors

Why We Are Important

Delivering life-saving drugs to hard-to-reach places

  • Malaria - Our patented Malaria drug is the industry's lowest cost drug focusing on the market for 263 million annual cases worldwide. The African region represents 94% of all Malaria cases. Zoar is one of the largest distributors of Malaria drugs to Africa.

    Notably, the company is the market leader in Antimalarial APIs and ranks as the world's third-largest contract manufacturer of Quinine salts.

  • Anti-Cancer Drugs - Our low-cost pharmaceutical manufacturing of anti-cancer drugs is being received as a cutting-edge break through. Our anti-cancer drug has been approved in Malaysia with pending initial distribution approval throughout South East Asia and beyond. Our anti-cancer drugs are projected to represent 50% of Zoar manufacturing and distribution base.

  • Orphan Drugs for Rare Diseases - Zoar has taken the profitable leadership role in the underserved and limited production market of Orphan Drugs for rare diseases. Biospace.com reported that the Orphan Drug Market is currently valued at around $170 - $215 billion with projections to reach over $500 billion by 2032, demonstrating significant growth driven by increasing awareness of rare diseases and supportive regulations for orphan drug development.

    Through Zoar patented low-cost pharmaceutical manufacturing technology, we are able to process critical care medicines for rare diseases. While leading drug manufacturers are finding it difficult to profitably compete in this specialized market, Zoar’ low cost manufacturing technologies has revitalized the unmet critical care for the Orphan Drug manufacturing market.

Where We Are Going

Our team of pharmaceutical engineers and scientists are committed to building on our success through continual research of profitable technology manufacturing breakthroughs that lower the cost and distribution of generic and patented drugs.

Active Pharmaceutical Ingredients

The Active Pharmaceutical Ingredients (APIs) business is a cornerstone of Zoar pharmaceutical operations.

orphan Drugs

Taking a leadership role in the underserved and the limited production market of orphan drugs for rare diseases.

CDMO

Our Contract Development and Manufacturing Organization (CDMO) is crucial in the pharmaceutical sector, offering essential services that help pharmaceutical companies bring new drugs to market efficiently.

Daphne-Huang

Daphne Huang

Chief Strategy Officer

Ms. Huang brings extensive public- and private-market experience in the pharmaceutical and technology sectors. She has served as Chief Financial Officer of Taro Pharmaceuticals and Gorilla Technology Group, and as Chief Financial Officer and Chief Operating Officer of Human Well Healthcare USA.

Markland Anthony

Chief Operating Officer

Markland Anthony is a seasoned professional with over 30 years of experience in Southeast Asia markets, currently serving as a key figure at Zoar Limited since its inception. He plays a pivotal role in shaping the company’s trajectory, culture, and performance, working with a global team that prioritizes ownership, speed, and impact. His expertise includes translating high-level objectives into actionable cross-departmental plans and fluency in English, Mandarin, and Cantonese. Before joining Zoar Limited, Markland was Vice President of Operations at Fung Shing Chemicals Limited.

Anthony Markland